mecasermin rinfabate (Takeda)

TAK-607 (mecasermin rinfabate) is a recombinant protein complex consisting of human insulin-like growth factor-I (rhIGF-I) and its primary binding protein, human insulin-like growth factor binding protein-3 (rhIGFBP-3). Originally developed by Insmed and later Shire (now Takeda), and currently licensed to Oak Hill Bio, it is designed as a replacement therapy for extremely premature infants. These infants often lack maternal IGF-1, which is critical for normal organ development. By stabilizing IGF-1 and extending its half-life, TAK-607 aims to prevent complications of prematurity, specifically retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and intraventricular hemorrhage (IVH). The drug was previously approved for growth hormone deficiency in children but was later discontinued for that indication to focus on neonatal complications.

Brand names

IPLEXSomatoKinePremiplex

Other names

rhIGF-I/rhIGFBP-3recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3